@ClermitInvest I am fundamentally with you and generally very bullish for the IBRX path. The rebound can of course come and IBRX is certainly in the biotech rebound due to its relaxed financial situation and (hopefully) final stage of unprofitability. But well... let's see, I still think it will take until the fall
